MwanzoLGND • NASDAQ
add
Ligand Pharmaceuticals Inc
$ 114.83
Kabla ya soko:(0.29%)-0.33
$ 114.50
Imefungwa: 10 Mac, 04:05:28 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 116.00
Bei za siku
$ 112.13 - $ 117.10
Bei za mwaka
$ 67.72 - $ 129.90
Thamani ya kampuni katika soko
2.17B USD
Wastani wa hisa zilizouzwa
elfu 94.34
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 42.81M | 52.35% |
Matumizi ya uendeshaji wa biashara | 51.74M | 21.41% |
Mapato halisi | -31.09M | -270.93% |
Kiwango cha faida halisi | -72.62 | -212.21% |
Mapato kwa kila hisa | 1.27 | -7.97% |
EBITDA | 10.31M | 85.57% |
Asilimia ya kodi ya mapato | 20.69% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 256.16M | 50.41% |
Jumla ya mali | 941.77M | 19.63% |
Jumla ya dhima | 111.34M | 29.00% |
Jumla ya hisa | 830.44M | — |
hisa zilizosalia | 19.26M | — |
Uwiano wa bei na thamani | 2.67 | — |
Faida inayotokana na mali | 0.44% | — |
Faida inayotokana mtaji | 0.50% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -31.09M | -270.93% |
Pesa kutokana na shughuli | 28.47M | 253.02% |
Pesa kutokana na uwekezaji | -38.62M | -275.56% |
Pesa kutokana na ufadhili | 20.39M | 283.59% |
Mabadiliko halisi ya pesa taslimu | 8.69M | 180.62% |
Mtiririko huru wa pesa | 43.18M | 325.86% |
Kuhusu
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop them further.
The company has been the subject of multiple regulatory investigations, negative shorts-seller reports and class action lawsuits amid allegations of securities fraud.
In 2018 its CEO was listed among the top five highest paid CEOs in San Diego. Wikipedia
Ilianzishwa
Sep 1987
Tovuti
Wafanyakazi
68
